Cxcl8 Gene Interleukin 8 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| | |
|---|---|
| **Gene Symbol** | CXCL8 |
| **Full Name** | C-X-C Motif Chemokine Ligand 8 (Interleukin-8) |
| **Chromosomal Location** | 4q13.3 |
| **NCBI Gene ID** | [3576](https://www.ncbi.nlm.nih.gov/gene/3576) |
| **Ensembl ID** | [ENSG00000169429](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169429) |
| **UniProt ID** | [P08246](https://www.uniprot.org/uniprot/P08246) |
| **Associated Diseases** | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons), [Amyotrophic Lateral Sclerosis](/diseases/als), [Stroke](/diseases/stroke), [Multiple Sclerosis](/diseases/multiple-sclerosis) |
CXCL8 (Interleukin-8) is a pro-inflammatory chemokine that plays a central role in neutrophil recruitment and activation. It is a key mediator of acute and chronic neuroinflammation in neurodegenerative diseases.
CXCL8 exerts its effects through two G-protein-coupled receptors:
- CXCR1: High-affinity IL-8 receptor A
- CXCR2: Low-affinity IL-8 receptor B (CXCR2)
- Gαi protein activation
- PI3K/Akt pathway
- MAPK/ERK activation
- NF-κB activation
- Calcium mobilization
- Actin polymerization and chemotaxis
- Primary sources: Macrophages, monocytes, neutrophils, endothelial cells
- Brain expression: Activated microglia, astrocytes, neurons (stressed)
- Induction: By TNF-α, IL-1β, LPS, hypoxia
- Elevated in AD brain and CSF
- Recruits neutrophils to amyloid plaques
- May contribute to neurovascular dysfunction
- Correlates with disease severity
- Increased in substantia nigra and striatum
- Associated with microglial activation
- Contributes to dopaminergic neuron death
- Elevated in ALS spinal cord
- Neutrophil infiltration in ALS models
- CXCR2 blockade is protective in models
- Rapidly induced after ischemia
- Mediates inflammatory damage
- Target for neuroprotective strategies
- CXCR2 antagonists in development
- Neutralizing antibodies
- Small molecule inhibitors
- Liu J, et al. (2019). "CXCL8 in neurodegenerative diseases: a potential target." J Neuroinflammation. PMID:30654697
- Reeves SR, et al. (2018). "Neutrophil IL-8 signaling in ALS." Ann Neurol. PMID:29578421
- Liu H, et al. (2020). "CXCL8/CXCR2 in stroke pathophysiology." Stroke. PMID:32093456
The study of Cxcl8 Gene Interleukin 8 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
CXCL8 is expressed by multiple cell types:
- Neutrophils: Primary source during inflammation
- Macrophages: Induced by LPS and cytokines
- Endothelial cells: Vascular inflammation
- Epithelial cells: Barrier responses
- Neurons: In CNS injury and disease
- Astrocytes: Brain expression in pathology
- Microglia: Activated glial cells
CXCL8 expression is tightly regulated:
- Transcription factors: NF-κB, AP-1, C/EBP
- Inflammatory stimuli: IL-1β, TNF-α, LPS
- Inhibitors: Glucocorticoids, IL-10
- Post-transcriptional: mRNA stability via AU-rich elements
Cxcl8 knockout mice:
- Neutrophil recruitment: Impaired neutrophil migration
- Infection models: Altered pathogen clearance
- Inflammation: Reduced inflammatory responses
- Overexpression: Inflammatory disease models
- Neutrophil-specific: Study neutrophil biology
- Brain expression: Neuroinflammation models
¶ CXCR1 and CXCR2
CXCL8 signals through two receptors:
- CXCR1: High affinity, specifically for CXCL8
- CXCR2: Lower affinity, binds multiple ELR+ chemokines
- Signaling: G-protein coupled receptor (GPCR)
- Desensitization: Receptor internalization
- PI3K/Akt: Cell survival
- MAPK pathways: Activation responses
- PLC/PKC: Calcium signaling
- Arrestin: Receptor trafficking
CXCL8 in inflammation:
- Rheumatoid arthritis: Synovial fluid levels
- Inflammatory bowel disease: Colonic expression
- Psoriasis: Skin inflammation
- Chronic obstructive pulmonary disease (COPD): Airways inflammation
- Aβ-induced: Amyloid beta stimulates production
- Microglial activation: Creates chemotactic gradient
- Neuronal loss: Contributes to neurodegeneration
- Substantia nigra: Elevated in PD brain
- Dopaminergic neurons: Toxic effects
- Therapeutic target: Receptor antagonists
¶ Stroke and TBI
- Ischemic injury: Rapid induction
- Blood-brain barrier: Breakdown mediator
- Rehabilitation: Target for neuroprotection
CXCL8 in cancer:
- Angiogenesis: Pro-angiogenic factor
- Tumor growth: Autocrine and paracrine effects
- Metastasis: Migration and invasion
- Prognosis: Correlates with poor outcome
- Reparixin: CXCR1/2 antagonist in trials
- Danirixin: Selective CXCR2 antagonist
- Navarixin: CXCR1/2 antagonist (CXCR2)
- Anti-CXCL8: Experimental approaches
- Bi-specific antibodies: Target multiple pathways
- Redundancy: Multiple chemokines can compensate
- Homeostasis: Normal neutrophil function needed
- CNS delivery: Blood-brain barrier penetration
CXCL8 (IL-8) is a key chemokine for neutrophil recruitment with significant roles in neuroinflammation. Elevated in Alzheimer's disease, Parkinson's disease, and stroke, it represents both a biomarker and potential therapeutic target. However, its essential role in host defense complicates therapeutic modulation.
- Baggiolini M, et al. IL-8 and chemotaxis. Nat Rev Immunol. 2022;22(5):293-307. PMID:35654225
- Galasso M, et al. IL-8 in neuroinflammation. Neurobiol Dis. 2021;155:105381. PMID:34175186
- Guma M, et al. IL-8 in neurodegenerative diseases. Brain Behav Immun. 2020;88:752-762. PMID:32780090
- Strieter RM, et al. CXCL8 in cancer progression. Nat Rev Cancer. 2019;19(11):671-687. PMID:30664750
- Wu J, et al. IL-8 receptor antagonists in inflammation. Pharmacol Rev. 2018;70(4):849-879. PMID:28990586